DK2292637T3 - Fremgangsmåde til proteinekstraktion - Google Patents
Fremgangsmåde til proteinekstraktion Download PDFInfo
- Publication number
- DK2292637T3 DK2292637T3 DK10180725.3T DK10180725T DK2292637T3 DK 2292637 T3 DK2292637 T3 DK 2292637T3 DK 10180725 T DK10180725 T DK 10180725T DK 2292637 T3 DK2292637 T3 DK 2292637T3
- Authority
- DK
- Denmark
- Prior art keywords
- solution
- antibody
- protein
- cells
- added
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (18)
1. Fremgangsmåde til ekstraktion af et antistof eller et antistoffragment fra E. coli-celler, omfattende: a) at sænke pH-værdien af en opløsning indeholdende E. coli-celler, der udtrykker et antistof eller et antistoffragment, til en pH- værdi, der ikke er højere end 4 eller 4,0 til 5,0; b) at tilsætte mindst en opløselighedsforstærker til opløsningen, hvor opløse-lighedsforstærkeren omfatter en divalent kation eller polyethylenimin; c) at opbryde cellerne til frigivelse af antistof eller antistoffragment til opløsningen; og d) at adskille cellerester fra frigjort antistof eller antistoffragment til opnåelse af et antistof- eller antistoffragmentprodukt beriget med antistoffet eller antistoffragmentet, hvor pH-værdien af opløsningen, der indeholder E. coli-celler sænkes, inden cellerne opbrydes; hvor antistoffet eller antistoffragmentet er et anti-VEGF Fab eller anti-vævsfaktor-antistof.
2. Fremgangsmåde ifølge krav 1, hvor opløsningens pH-værdi sænkes til en pH-værdi på 4,0 til 4,5, eller hvor opløsningens pH-værdi sænkes til en pH-værdi på 4,0.
3. Fremgangsmåde ifølge krav 1 eller krav 2, hvor opløsningens pH-værdi sænkes ved tilsætning af en syre, der har en pufferkapacitet ved den sænkede pH-værdi.
4. Fremgangsmåde ifølge krav 3, hvor syren er citronsyre.
5. Fremgangsmåde ifølge krav 3 eller 4, hvor syren tilsættes i en koncentration på ca. 50 til 100 mM.
6. Fremgangsmåde ifølge et hvilket som helst af kravene 1-5, hvor adskillelsen omfatter centrifugering.
7. Fremgangsmåde ifølge krav 6, yderligere omfattende oprensning af antistoffet eller antistoffragmentet fra antistof- eller antistoffragmentproduktet.
8. Fremgangsmåde ifølge krav 7, hvor oprensningen omfatter søjlekromatografi.
9. Fremgangsmåde ifølge krav 8, hvor søjlekromatografien er expanded bedkromatografi.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 1-9, hvor den mindst ene opløselighedsforstærker tilsættes til opløsningen inden eller samtidig med sænkningen af pFI-værdien.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 1-10, hvor opløse-lighedsforstærkeren tilsættes i vandig form, i en mængde, der resulterer i en endelig koncentration på fra ca. 30 mM til ca. 120 mM.
12. Fremgangsmåde ifølge et hvilket som helst af kravene 1-11, hvor den mindst ene opløselighedsforstærker omfatter en divalent kation.
13. Fremgangsmåde ifølge krav 12, hvor den divalente kation er magnesium eller calcium.
14. Fremgangsmåde ifølge krav 12, hvor den mindst ene opløselighedsforstærker omfatter magnesiumsulfat eller magnesiumchlorid.
15. Fremgangsmåde ifølge et hvilket som helst af kravene 1-10 og 12-14, hvor den divalente kation tilsættes i en mængde, der resulterer i en endelig koncentration på ca. 10 mM til ca. 150 mM.
16. Fremgangsmåde ifølge et hvilket som helst af kravene 1-11, hvor den mindst ene opløselighedsforstærker omfatter polyethylenimin.
17. Fremgangsmåde ifølge et hvilket som helst af kravene 1-10 og 16, hvor polyethylenimin tilsættes i en mængde, der resulterer i en endelig koncentra- tion på ca. 0,2 % til ca. 0,3% vol/vol af en 50% v/vol opløsning.
18. Fremgangsmåde ifølge et hvilket som helst af kravene 1-17, hvor den mindst ene opløselighedsforstærker omfatter en divalent kation og polyethy-lenimin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40865302P | 2002-09-06 | 2002-09-06 | |
| EP03752068A EP1539798B1 (en) | 2002-09-06 | 2003-09-05 | Process for protein extraction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2292637T3 true DK2292637T3 (da) | 2016-04-04 |
Family
ID=31978651
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10180725.3T DK2292637T3 (da) | 2002-09-06 | 2003-09-05 | Fremgangsmåde til proteinekstraktion |
| DK03752068.1T DK1539798T3 (da) | 2002-09-06 | 2003-09-05 | Fremgangsmåde til proteinekstraktion |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03752068.1T DK1539798T3 (da) | 2002-09-06 | 2003-09-05 | Fremgangsmåde til proteinekstraktion |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US6967241B2 (da) |
| EP (2) | EP1539798B1 (da) |
| JP (2) | JP5519089B2 (da) |
| AT (1) | ATE489400T1 (da) |
| AU (2) | AU2003270380B2 (da) |
| CA (1) | CA2497209C (da) |
| CY (1) | CY1111111T1 (da) |
| DE (1) | DE60335119D1 (da) |
| DK (2) | DK2292637T3 (da) |
| ES (2) | ES2565781T3 (da) |
| HK (2) | HK1076287A1 (da) |
| HU (1) | HUE027196T2 (da) |
| PT (1) | PT1539798E (da) |
| SI (2) | SI1539798T1 (da) |
| WO (1) | WO2004022581A1 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2477054C (en) * | 2002-02-25 | 2011-05-31 | Daniel R. Burnett | Vesicular shunt for the drainage of excess fluid |
| DK2292637T3 (da) | 2002-09-06 | 2016-04-04 | Genentech Inc | Fremgangsmåde til proteinekstraktion |
| CA2853623C (en) * | 2005-12-23 | 2017-03-21 | Vysera Biomedical Limited | A medical device suitable for treating reflux from a stomach to an oesophagus |
| WO2008127305A2 (en) * | 2006-11-01 | 2008-10-23 | Biogen Idec Ma Inc. | Method of isolating biomacromolecules using low ph and divalent cations |
| US9017966B2 (en) | 2007-05-23 | 2015-04-28 | Nature Technology Corporation | E. coli plasmid DNA production |
| US20110160836A1 (en) * | 2008-06-20 | 2011-06-30 | Vysera Biomedical Limited | Valve device |
| WO2009153771A1 (en) | 2008-06-20 | 2009-12-23 | Vysera Biomedical Limited | Esophageal valve |
| US20100114327A1 (en) * | 2008-06-20 | 2010-05-06 | Vysera Biomedical Limited | Valve |
| DK2512574T3 (da) * | 2009-12-18 | 2018-01-08 | Coloplast As | Urologisk anordning |
| US8992410B2 (en) | 2010-11-03 | 2015-03-31 | Vysera Biomedical Limited | Urological device |
| JP5511112B2 (ja) * | 2011-06-14 | 2014-06-04 | 有限会社バイオメディカルリサーチグループ | 菌体破砕物及びその配合物 |
| RU2014124842A (ru) * | 2011-11-21 | 2015-12-27 | Дженентек, Инк. | Очистка анти-с-мет антител |
| CA2858301C (en) | 2011-12-19 | 2021-01-12 | Vysera Biomedical Limited | A luminal prosthesis and a gastrointestinal implant device |
| CN106068272B (zh) * | 2013-09-24 | 2021-08-03 | 爱力根制药国际有限公司 | 提取蛋白质的方法 |
| CA2965440C (en) * | 2014-10-23 | 2023-05-23 | Basf Se | Method for producing a prefabricated building material |
| CN107580630A (zh) * | 2015-05-15 | 2018-01-12 | 葛兰素集团有限公司 | 产生重组蛋白的方法 |
| WO2018235958A1 (ja) * | 2017-06-23 | 2018-12-27 | Ｓｐｉｂｅｒ株式会社 | タンパク質の精製方法、タンパク質溶液の製造方法、及びタンパク質成形体の製造方法 |
| CN110878118B (zh) * | 2018-09-06 | 2023-04-18 | 深圳翰宇药业股份有限公司 | 度拉糖肽的纯化方法与纯化试剂 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4173766A (en) * | 1977-09-16 | 1979-11-06 | Fairchild Camera And Instrument Corporation | Insulated gate field-effect transistor read-only memory cell |
| DE3432196A1 (de) | 1984-09-01 | 1986-03-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neues mechanisches aufschlussverfahren von bakterienzellen zur isolierung von rekombinant hergestellten peptiden |
| HU201775B (en) | 1984-12-27 | 1990-12-28 | Suntory Ltd | Process for purifying interferon |
| US4683294A (en) * | 1985-04-03 | 1987-07-28 | Smith Kline Rit, S.A. | Process for the extraction and purification of proteins from culture media producing them |
| US5196323A (en) * | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
| DE3515336C2 (de) | 1985-04-27 | 1994-01-20 | Boehringer Ingelheim Int | Verfahren zur Herstellung und Reinigung von â-Interferon |
| IL78703A (en) | 1985-05-10 | 1993-02-21 | Benzon Alfred | Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials |
| US4721573A (en) * | 1986-03-06 | 1988-01-26 | J. T. Baker Chemical Company | Use of sulfonic derivatives of acylated polyethyleneimine bonded phase silica products |
| US5196823A (en) * | 1986-04-24 | 1993-03-23 | Multitecno S.P.A. | Deratization apparatus with remote terminals |
| EP0252588A3 (en) * | 1986-05-12 | 1989-07-12 | Smithkline Beecham Corporation | Process for the isolation and purification of p. falciparum cs protein expressed in recombinant e. coli, and its use as a vaccine |
| US4801686A (en) * | 1986-09-04 | 1989-01-31 | Immunex Corporation | Purification of recombinant interleukin-1 |
| US5085779A (en) * | 1989-06-07 | 1992-02-04 | J. T. Baker, Inc. | Polyethyleneimine matrixes for affinity chromatography |
| US4988798A (en) * | 1990-01-22 | 1991-01-29 | Pitman-Moore, Inc. | Method for recovering recombinant proteins |
| JP3678311B2 (ja) | 1992-10-16 | 2005-08-03 | 京セラミタ株式会社 | ヒドラゾン系化合物およびそれを用いた電子写真感光体 |
| AU7217094A (en) * | 1993-07-02 | 1995-01-24 | Incyte Pharmaceuticals, Inc. | Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same |
| US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JPH11511650A (ja) * | 1995-05-02 | 1999-10-12 | アレクション・ファーマシューティカルズ・インク | 改変されたミエリンタンパク質分子 |
| US5760189A (en) * | 1995-06-02 | 1998-06-02 | Genetics Institute, Inc. | Protein recovery & purification methods |
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| PT998486E (pt) | 1997-06-13 | 2007-08-21 | Genentech Inc | ''recuperação de proteínas por cromatografia seguida de filtração numa camada carregada'' |
| US6768165B1 (en) * | 1997-08-01 | 2004-07-27 | Saifun Semiconductors Ltd. | Two bit non-volatile electrically erasable and programmable semiconductor memory cell utilizing asymmetrical charge trapping |
| US20020010145A1 (en) * | 1999-07-12 | 2002-01-24 | Willson Richard C. | Apparatus, methods and compositions for biotechnical separations |
| AU4312201A (en) | 1999-12-10 | 2001-06-18 | Genespan Corporation | Isolation and purification of nucleic acids |
| ATE405650T1 (de) | 2000-12-14 | 2008-09-15 | Genentech Inc | Produktion von ganzen antikörpern in prokaryontischen zellen |
| KR100395762B1 (ko) * | 2001-07-31 | 2003-08-21 | 삼성전자주식회사 | 비휘발성 메모리 소자 및 그 제조방법 |
| US20040152260A1 (en) * | 2001-09-07 | 2004-08-05 | Peter Rabkin | Non-volatile memory cell with non-uniform surface floating gate and control gate |
| US6440797B1 (en) * | 2001-09-28 | 2002-08-27 | Advanced Micro Devices, Inc. | Nitride barrier layer for protection of ONO structure from top oxide loss in a fabrication of SONOS flash memory |
| KR100426483B1 (ko) * | 2001-12-22 | 2004-04-14 | 주식회사 하이닉스반도체 | 플래쉬 메모리 셀의 제조 방법 |
| US6624028B1 (en) * | 2002-03-04 | 2003-09-23 | Megawin Technology Co., Ltd. | Method of fabricating poly spacer gate structure |
| US7042045B2 (en) * | 2002-06-04 | 2006-05-09 | Samsung Electronics Co., Ltd. | Non-volatile memory cell having a silicon-oxide nitride-oxide-silicon gate structure |
| DK2292637T3 (da) * | 2002-09-06 | 2016-04-04 | Genentech Inc | Fremgangsmåde til proteinekstraktion |
| KR100446632B1 (ko) * | 2002-10-14 | 2004-09-04 | 삼성전자주식회사 | 비휘발성 ｓｏｎｓｎｏｓ 메모리 |
| ES2287687T3 (es) * | 2003-01-09 | 2007-12-16 | Genentech, Inc. | Purificacion de polipeptidos. |
| US6885590B1 (en) * | 2003-01-14 | 2005-04-26 | Advanced Micro Devices, Inc. | Memory device having A P+ gate and thin bottom oxide and method of erasing same |
| EP1598075A1 (en) * | 2004-05-21 | 2005-11-23 | LEK Pharmaceuticals d.d. | Process for the isolation and / or purification of proteins |
-
2003
- 2003-09-05 DK DK10180725.3T patent/DK2292637T3/da active
- 2003-09-05 JP JP2004534717A patent/JP5519089B2/ja not_active Expired - Lifetime
- 2003-09-05 AT AT03752068T patent/ATE489400T1/de active
- 2003-09-05 SI SI200331944T patent/SI1539798T1/sl unknown
- 2003-09-05 EP EP03752068A patent/EP1539798B1/en not_active Expired - Lifetime
- 2003-09-05 DK DK03752068.1T patent/DK1539798T3/da active
- 2003-09-05 ES ES10180725.3T patent/ES2565781T3/es not_active Expired - Lifetime
- 2003-09-05 WO PCT/US2003/028007 patent/WO2004022581A1/en active Application Filing
- 2003-09-05 US US10/655,874 patent/US6967241B2/en not_active Expired - Lifetime
- 2003-09-05 AU AU2003270380A patent/AU2003270380B2/en not_active Expired
- 2003-09-05 ES ES03752068T patent/ES2355088T3/es not_active Expired - Lifetime
- 2003-09-05 SI SI200332468T patent/SI2292637T1/sl unknown
- 2003-09-05 PT PT03752068T patent/PT1539798E/pt unknown
- 2003-09-05 CA CA 2497209 patent/CA2497209C/en not_active Expired - Lifetime
- 2003-09-05 EP EP10180725.3A patent/EP2292637B1/en not_active Expired - Lifetime
- 2003-09-05 DE DE60335119T patent/DE60335119D1/de not_active Expired - Lifetime
- 2003-09-05 HU HUE10180725A patent/HUE027196T2/hu unknown
-
2005
- 2005-10-31 HK HK05109683.8A patent/HK1076287A1/xx not_active IP Right Cessation
- 2005-10-31 US US11/264,300 patent/US7662934B2/en not_active Expired - Lifetime
- 2005-10-31 HK HK11105075.4A patent/HK1151041A1/zh not_active IP Right Cessation
-
2006
- 2006-09-29 US US11/537,565 patent/US7713707B2/en active Active
-
2010
- 2010-01-19 JP JP2010008895A patent/JP2010111700A/ja active Pending
- 2010-01-26 US US12/694,223 patent/US8232374B2/en not_active Expired - Lifetime
- 2010-05-10 US US12/777,211 patent/US8383773B2/en not_active Expired - Lifetime
- 2010-06-10 AU AU2010202423A patent/AU2010202423A1/en not_active Abandoned
-
2011
- 2011-01-17 CY CY20111100054T patent/CY1111111T1/el unknown
-
2012
- 2012-06-29 US US13/539,126 patent/US8940875B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7713707B2 (en) | Process for protein extraction | |
| Westoby et al. | Effects of solution environment on mammalian cell fermentation broth properties: enhanced impurity removal and clarification performance | |
| AU2007351548B2 (en) | Method of isolating biomacromolecules using low pH and divalent cations | |
| AU2014211438B2 (en) | Method of producing a protein | |
| AU745806B2 (en) | Adsorption chromatography | |
| US20220073560A1 (en) | Method for transferring a batch production process to a continuous production process | |
| Balasundaram et al. | Dual salt precipitation for the recovery of a recombinant protein from Escherichia coli | |
| AU2002308753B2 (en) | Acetate-free purification of plasmid DNA on hydroxyapatite | |
| JP2001139600A (ja) | Ｉｌ−６ｒ・ｉｌ−６融合蛋白質の精製方法 | |
| Pattnaik et al. | Use of membrane technology in bioprocessing therapeutic proteins from inclusion bodies of E. coli | |
| Bird | A study of the use of fractionation diagrams for the study of bioprocess interactions |